Vest Financial LLC Has $48.74 Million Stake in Kenvue Inc. $KVUE

Key Points

• Vest Financial LLC has decreased its stake in Kenvue Inc. (KVUE) by 11.7% during the 2nd quarter, now holding about 0.12% of the company, valued at approximately $48.74 million.
• Recent price target cuts from various analysts reflect a bearish outlook, with Bank of America lowering its target from $25 to $21, and Barclays from $20 to $17.
• Kenvue has announced a quarterly dividend increase to $0.2075 per share, resulting in a dividend yield of 5.0%.

Vest Financial LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 11.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,328,506 shares of the company's stock after selling 309,773 shares during the quarter. Vest Financial LLC owned about 0.12% of Kenvue worth $48,736,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pittenger & Anderson Inc. bought a new position in Kenvue during the 1st quarter worth approximately $30,000. Trust Co. of Vermont boosted its stake in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after acquiring an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC bought a new position in Kenvue during the 1st quarter worth approximately $36,000. Truvestments Capital LLC bought a new position in Kenvue during the 1st quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the topic of a number of research reports. Bank of America cut their price target on shares of Kenvue from $25.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, October 8th. Barclays cut their price target on shares of Kenvue from $20.00 to $17.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 1st. Evercore ISI cut their price target on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating on the stock in a research note on Tuesday, September 23rd. Canaccord Genuity Group cut their price target on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Citigroup cut their price objective on shares of Kenvue from $20.00 to $17.00 and set a "neutral" rating on the stock in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $21.18.

Kenvue Stock Down 1.0%

Shares of KVUE stock opened at $16.68 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The firm's 50-day moving average is $19.15 and its 200-day moving average is $21.31. The stock has a market cap of $32.00 billion, a price-to-earnings ratio of 22.53, a PEG ratio of 2.39 and a beta of 0.72. Kenvue Inc. has a 52-week low of $15.47 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. During the same period in the prior year, the firm earned $0.32 EPS. Kenvue's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio is presently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.